Top-News

ONCOLYTICS BIOTECH News

Aktie
WKN:  936874 ISIN:  CA6823101077 US-Symbol:  ONCYF
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
141,75 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 13.09.2018

ONCOLYTICS BIOTECH News

30.06.21 - PR Newswire
Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference
Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference Presentation to take place on Wednesday, July 14 at 4:30 p.m. ET PR Newswire
20.05.21 - PR Newswire
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-​of-Concept for Pelareorep-​Checkpoint Inhibitor Combination in Pancreatic Cancer The ...
20.05.21 - PR Newswire
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-​of-Concept for Pelareorep-​Checkpoint Inhibitor Combination in Pancreatic Cancer PR ...
13.05.21 - PR Newswire
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference PR Newswire
13.05.21 - PR Newswire
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference PR Newswire
10.05.21 - PR Newswire
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders PR Newswire
10.05.21 - PR Newswire
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders PR Newswire
07.05.21 - PR Newswire
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results PR Newswire
07.05.21 - PR Newswire
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results PR Newswire
30.04.21 - PR Newswire
Oncolytics Biotech® Announces Annual General Meeting
Oncolytics Biotech® Announces Annual General Meeting PR Newswire
30.04.21 - PR Newswire
Oncolytics Biotech® Announces Annual General Meeting
Oncolytics Biotech® Announces Annual General Meeting PR Newswire
29.04.21 - PR Newswire
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting PR Newswire
29.04.21 - PR Newswire
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting PR Newswire
12.04.21 - PR Newswire
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study PR Newswire
12.04.21 - PR Newswire
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study PR Newswire
12.04.21 - PR Newswire
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-​based Combination Therapies at the AACR Annual Meeting - Pelareorep enhances anti-​tumor efficacy of PARP-1 and ...
12.04.21 - PR Newswire
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
Oncolytics Biotech® Presents Preclinical Data on Pelareorep-​based Combination Therapies at the AACR Annual Meeting PR Newswire
09.04.21 - PR Newswire
IIROC Trade Resumption - ONC
IIROC Trade Resumption - ONC Canada NewsWire
09.04.21 - PR Newswire
IIROC Trading Halt - ONC
IIROC Trading Halt - ONC Canada NewsWire
08.04.21 - PR Newswire
Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »